Disorders

Parkinsons’ Disease Award - 2007

Dr Janetta G Culvenor was the recipient of Brain Foundation grant funding in 2007

Parkinsons’ Disease Award

Parkinsons’ Disease Award
Deciphering the biochemical properties of Parkinson’s Disease-associated Leucine-rich Repeat Kinase 2.
Dr Janetta G Culvenor
Department of Pathology and Centre for Neuroscience, University of Melbourne
Funded By Ami Olian Memorial Fund, Guildford Inner Wheel and the Estates of: Grace Jeanie Admans, Esther Hennessy, Leslie Keller and Bruce Smith
Co-Investigators : Associate Professor Heung-Chin Cheng, Dr Terrence D Mulhern, Dr Nicholas A Williamson
Janetta Culvenor

Parkinsons’ Disease Award funded by Ami Olian Memorial Fund, Guildford Inner Wheel and the Estates of: Grace Jeanie Admans, Esther Hennessy, Leslie Keller and Bruce Smith
Deciphering the biochemical properties of Parkinson’s Disease-associated Leucine-rich Repeat Kinase 2.

Dr Janetta G Culvenor
Department of Pathology and Centre for Neuroscience, University of Melbourne
Co-Investigators: Associate Professor Heung-Chin Cheng, Dr Terrence D Mulhern, Dr Nicholas A Williamson

 

This project will investigate biochemical features of the kinase domain of the Leucine-rich repeat kinase 2 (LRRK2). LRRK2 is a large complex brain protein (2527 amino acids) encoded by the gene most frequently mutated in genetically inherited autosomal dominant Parkinson’s disease (Paisan-Ruiz et al. 2004). Very little is known about the cellular function of this recently identified key protein. Phosphorylation of molecules acts as a switch to turn many enzymes on or off.  Thus LRRK2 as a kinase (phosphorylating enzyme) can regulate the function or activity of other proteins.  LRRK2 can also phosphorylate itself and thereby regulate its own activity in response to various stimuli thus the autophosphorylation is very important as it may cause a change in the activity of LRRK2 and eventually affect a large number of downstream events. The domain structure for LRRK2 is shown in Fig.1. We are currently studying recombinant LRRK2 regions by expression and purification in insect cell culture as utilized also for the study of the Parkinson’s associated PINK1 kinase (Culvenor, Cheng ref 14 above, 2006). Segments of the protein that we have expressed are shown in Fig. 2. We have established that purified truncated recombinant LRRK2 kinase enzyme can phosphorylate the artificial substrate, myelin basic protein and that our purified LRRK2 shows strong autophosphorylation (Fig.3). We have demonstrated that artificial substrate and autophosphorylation is enhanced by the most common Parkinson’s disease mutation G2019S.

 

We hypothesize that: LRRK2 exerts its Parkinson’s pathogenic effect by phosphorylation of a critical protein which increases neuronal cell death and that autophosphorylation activates LRRK2 and enhances its pathogenic effect.

 

In this project the major aim is: To identify the autophosphorylation site for LRRK2, analyse how autophosphorylation modulates LRRK2 kinase activity, and generate a phosphospecific antibody for detection and monitoring of the phosphorylation and activation status of LRRK2 in cells and samples from Parkinson’s disease patients.

 

Once the autophosphorylation site is identified, we will perform site-directed mutagenesis to mutate the site to alanine. The kinase activity of the mutant and the autophosphorylated wild type enzyme will be compared. The study will reveal how autophosphorylation modulates LRRK2 kinase activity and the LRRK2 protein’s interaction in known biochemical pathways causing Parkinson’s Disease.

Brain FoundationThe Brain Foundation is the largest, independent funder of brain and spinal injury research in Australia. We believe research is the pathway to recovery.
PLEASE HELP US BY DONATING TO OUR RESEARCH PROGRAM.